MRSN•benzinga•
Mersana Therapeutics shares were trading higher after the company's XMT-1660 was granted FDA Fast Track Designation for treatment of triple-negative breast cancer.
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 12, 2022 by benzinga